Clostridium difficile infection in the community: Are proton pump inhibitors to blame?

World Journal of Gastroenterology

Volumn 19, Issue 40, 2013, Pages 6710-6713

  Freedberg, Daniel E ^a   Abrams, Julian A ^a  

^a Department of Medicine   (United States)

Author keywords

Anti bacterial agents; Clostridium difficile; Disease outbreaks; Epidemics; Pharmacoepidemiology; Proton pump inhibitors; Pseudomembranous enterocolitis; Public health

Indexed keywords

ANTIBIOTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNICABLE DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EXPOSURE; HEALTH CARE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MICROBIOME; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DISEASE OUTBREAKS; EPIDEMICS; PHARMACOEPIDEMIOLOGY; PROTON PUMP INHIBITORS; PSEUDOMEMBRANOUS ENTEROCOLITIS; PUBLIC HEALTH;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; POPULATION SURVEILLANCE;

EID: 84887013621     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i40.6710     Document Type: Article

References (36)

1. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-1227 [PMID: 17926270 DOI: 10.1086/522676]
2. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359: 1932-1940 [PMID: 18971494 DOI: 10.1056/NEJMra0707500359/18/1932]
3. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449 [PMID: 16322602 DOI: 10.1056/ NEJMoa051639]
4. Gravel D, Miller M, Simor A, Taylor G, Gardam M, Mc-Geer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48: 568-576 [PMID: 19191641 DOI: 10.1086/5 9670310.1086/596703]
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, Mc-Donald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455 [PMID: 20307191 DOI: 10.1086/651706]
6. Kyne L, Merry C, O'Connell B, Keane C, O'Neill D. Community-acquired Clostridium difficile infection. J Infect 1998; 36: 287-288 [PMID: 9661938]
7. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1201-1205 [PMID: 16319813]
8. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107: 89-95 [PMID: 22108454 DOI: 10.1038/ajg.2011.398ajg2011398]
9. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, Farley MM, Dumyati GK, Wilson LE, Beldavs ZG, Dunn JR, Gould LH, MacCannell DR, Gerding DN, McDonald LC, Lessa FC. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013; 173: 1359-1367 [PMID: 23780507 DOI: 10.1001/jamainternmed.2013.70561697791]
10. Rifkin GD, Fekety FR, Silva J. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 1977; 2: 1103-1106 [PMID: 73011]
11. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998; 128: 989-995 [PMID: 9625685]
12. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-534 [PMID: 625309 DOI: 10.1056/NEJM197803092981003]
13. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for communityassociated Clostridium difficile infection: a nested casecontrol study. BMC Infect Dis 2011; 11: 194 [PMID: 21762504 DOI: 10.1186/1471-2334-11-1941471-2334-11-194]
14. Naggie S, Miller BA, Zuzak KB, Pence BW, Mayo AJ, Nicholson BP, Kutty PK, McDonald LC, Woods CW. A casecontrol study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124: 276. e1-276. e7 [PMID: 21396512 DOI: 10.1016/j.amj med.2010.10.013S0002-9343(10)00925-3]
15. Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J, McDonald LC. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010; 16: 197-204 [PMID: 20113547 DOI: 10.3201/ eid1602.090953]
16. Bauer MP, Goorhuis A, Koster T, Numan-Ruberg SC, Hagen EC, Debast SB, Kuijper EJ, van Dissel JT. Communityonset Clostridium difficile-associated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea. Neth J Med 2008; 66: 207-211 [PMID: 18490799]
17. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-1019 [PMID: 22525304 DOI: 10.1038/ajg.2012.108ajg2012108]
18. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 1001-1010 [PMID: 22710578 DOI: 10.1038/ajg.2012.179]
19. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43: 1272-1276 [PMID: 17051491]
20. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179: 767-772 [PMID: 18838451 DOI: 10.1503/cmaj.071812179/8/767]
21. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007; 45: 1141-1151 [PMID: 17918075]
22. Centers for Disease Control and Prevention. Emerging Infections Program-Healthcare-associated Infections Project. Technical Information-Measuring the Scope of Clostridium difficile Infection in the United States. Available from: URL: http://www.cdc.gov/hai/eip/cdiff_techinfo.html
23. Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available from: URL: http://www.fda. gov/drugs/drugsafety/ucm290510.htm
24. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944 [PMID: 19258584 DOI: 10.1001/ jama.2009.261301/9/937]
25. Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, Francis N, Lyons RA, Dunstan F. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol 2013; 108: 1094-1100 [PMID: 23588238 DOI: 10.1038/ajg.2013.30ajg201330]
26. Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol 2012; 107: 1020-1021 [PMID: 22764024 DOI: 10.1038/ ajg.2012.174ajg2012174]
27. McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441 [PMID: 16322603]
28. Garcia-Mazcorro JF, Suchodolski JS, Jones KR, Clark-Price SC, Dowd SE, Minamoto Y, Markel M, Steiner JM, Dossin O. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol Ecol 2012; 80: 624-636 [PMID: 22324305 DOI: 10.1111/j.1574-6941.2012.01331.x]
29. Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010; 5: e9836 [PMID: 20352091 DOI: 10.1371/journal.pone.0009836]
30. Bühling A, Radun D, Müller WA, Malfertheiner P. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 2001; 15: 1445-1452 [PMID: 11552917]
31. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1: 56-66 [PMID: 18043614]
32. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, Masson L, Tellis PA, Brousseau R. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 2010; 202: 1877-1884 [PMID: 21050115 DOI: 10.1086/657319]
33. Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf 2011; 20: 1035-1042 [PMID: 21833992 DOI: 10.1002/pds.2198]
34. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995 [PMID: 16414946]
35. Marwick CA, Yu N, Lockhart MC, McGuigan CC, Wiuff C, Davey PG, Donnan PT. Community-associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case-control. J Antimicrob Chemother 2013; Epub ahead of print [PMID: 23825381]
36. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98: 51-58 [PMID: 12526936]